2011
DOI: 10.1200/jco.2010.30.9245
|View full text |Cite
|
Sign up to set email alerts
|

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

Abstract: Decitabine administered in 6-week cycles is active in older patients with higher-risk MDS, resulting in improvements of OS and AMLFS (nonsignificant), of PFS and AML transformation (significant), and of QOL. Short MDS duration was an independent adverse prognosticator.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

15
355
2
7

Year Published

2015
2015
2023
2023

Publication Types

Select...
4
3

Relationship

1
6

Authors

Journals

citations
Cited by 491 publications
(379 citation statements)
references
References 22 publications
15
355
2
7
Order By: Relevance
“…Crossover to the experimental arm was prohibited. Decitabine (15 mg/m 2 in two doses over 2 h each) was given intravenously every 8 h for 3 days in 6-week cycles [8]. If regeneration of hematologic parameters was insufficient, the interval between cycles could be extended up to 10 weeks.…”
Section: Methodsmentioning
confidence: 99%
See 3 more Smart Citations
“…Crossover to the experimental arm was prohibited. Decitabine (15 mg/m 2 in two doses over 2 h each) was given intravenously every 8 h for 3 days in 6-week cycles [8]. If regeneration of hematologic parameters was insufficient, the interval between cycles could be extended up to 10 weeks.…”
Section: Methodsmentioning
confidence: 99%
“…Eligibility criteria of trial 06011 (clinicaltrials.gov Id NCT00043134) have been previously reported [8] and included the following: patients ≥60 years old; primary or treatment-related MDS or chronic myelomonocytic leukemia (CMML) according to FAB criteria [9]; International Prognostic Scoring System (IPSS) intermediate-1, intermediate-2, or high risk [1]; BM blasts of 11 to 30 %, or ≤10 % and poor cytogenetics according to IPSS criteria; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; and ineligible for intensive chemotherapy as judged by the treating physician. No previous treatment with standard chemotherapy or a hypomethylating agent was allowed.…”
Section: Patientsmentioning
confidence: 99%
See 2 more Smart Citations
“…Although decitabine is another effective HMA for MDS and AML (Lübbert et al. 2011; Kantarjian et al. 2012), the prognosis after decitabine failure is also poor (Jabbour et al.…”
Section: Introductionmentioning
confidence: 99%